Search results for "COMBINATION"

showing 10 items of 1379 documents

X-Linked Dilated Cardiomyopathy.

1995

We report on a family with a severe form of X-linked dilated cardiomyopathy (DCM). Two brothers, the elder requiring heart transplantation, and a maternal cousin presented elevated creatine kinase levels, increased right ventricular diameters and electrocardiographic abnormalities. All complained of exertional cramping myalgia, but none had muscle weakness or a pathological electromyogram. Muscle biopsies of these individuals revealed a mild myopathic picture with atrophic type I and hypertrophic type II fibers. Immunofluorescence using N- and C-terminal antibodies (dys-2, dys-3) against the dystrophin protein showed preserved, but reduced intensity of staining of the sarcolemmal membranes.…

AdultCardiomyopathy DilatedGenetic MarkersMaleX ChromosomeGenetic LinkageBiopsyMyosinsImmunofluorescencePolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyDystrophinExonHistory and Philosophy of ScienceWestern blotmedicineHumansRNA MessengerMuscle SkeletalDNA PrimersSequence DeletionSouthern blotRecombination Geneticbiologymedicine.diagnostic_testMyocardiumGeneral NeuroscienceChromosome MappingDilated cardiomyopathyExonsmusculoskeletal systemmedicine.diseaseMolecular biologyPedigreeAlternative Splicingbiology.proteinFemaleCreatine kinaseLod ScoreAntibodyDystrophinAnnals of the New York Academy of Sciences
researchProduct

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…

2009

The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…

AdultCarotid Artery Diseasesmedicine.medical_specialtyImmunologyTNFGastroenterologyArthritis RheumatoidRheumatologyInternal medicineRheumatoid arthritis TNF DMARDs AtherosclerosisFemale patientmedicineHumansImmunology and AllergyRheumatoid arthritiUltrasonographyTumor Necrosis Factor-alphaVascular diseasebusiness.industryAntagonistMiddle AgedAtherosclerosismedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaDMARDMethotrexateTreatment OutcomeIntima-media thicknessAntirheumatic AgentsRheumatoid arthritiscardiovascular systemDrug Therapy CombinationFemaleMethotrexateTumor necrosis factor alphaTunica IntimaTunica Mediabusinessmedicine.drugRheumatology International
researchProduct

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

2003

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…

AdultCyclopropanesMalePulmonary and Respiratory MedicineBudesonideAdolescentmedicine.drug_classAcetatesSulfidesFluticasone propionatechemistry.chemical_compoundDouble-Blind Methodimmune system diseasesAdministration InhalationHumansMedicineSingle-Blind MethodAnti-Asthmatic AgentsBudesonideMontelukastAgedAsthmaLeukotriene E4business.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeEditorialchemistryAnesthesiaQuinolinesCorticosteroidDrug Therapy CombinationFemaleOnset of actionSalmeterolbusinessmedicine.drugThorax
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Influence of Senna, Fibre, and Fibre + Senna on Colonic Transit in Loperamide-induced Constipation

1993

Retarded colonic transit and disturbed defecation are the most prominent pathophysiological mechanisms in constipation. Both may be influenced by bulking agents and by laxatives such as senna. Direct measurements of the influence of such substances on colonic transit are rare mainly because of technical problems. We measured gastric emptying, small and large intestinal transit in 24 healthy volunteers by a newly developed method employing a metal detector. Twelve persons taking a normal diet received loperamide in a dose sufficient to double the individual transit time. All subjects measured gastrointestinal transit time under normal conditions and with Sennatin containing purified sennosid…

AdultDietary FiberMalemedicine.medical_specialtyLoperamideConstipationAdolescentSennaCassiaLoperamideGastroenterologyFecesCassiaInternal medicinemedicineHumansGastrointestinal TransitFecesPharmacologyPlants Medicinalbiologybusiness.industrySenna Extractdigestive oral and skin physiologyGeneral Medicinebiology.organism_classificationIntestinesDrug CombinationsGastric EmptyingDefecationFemaleDietary fibermedicine.symptombusinessConstipationmedicine.drugPharmacology
researchProduct

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation

2000

Clinical trials using quadruple immunosuppression that include the combination of tacrolimus and mycophenolate mofetil have been shown to reduce the incidence of acute rejection episodes in simultaneous pancreas-kidney (SPK) transplantation. In an attempt to obtain a low rejection rate without antibody induction therapy, we undertook a prospective study of combined tacrolimus and mycophenolate mofetil and steroids as primary immunosuppression for SPK transplantation. In this study, we analyzed 17 patients who received low-dose intravenous tacrolimus as induction therapy. This was combined with oral tacrolimus, mycophenolate mofetil, and steroids as the primary immunosuppression regimen. The…

AdultGraft RejectionMaleNephrologymedicine.medical_specialtyBiopsymedicine.medical_treatmentUrinary Bladderchemical and pharmacologic phenomenaPancreas transplantationGastroenterologyTacrolimusMycophenolic acidInternal medicinemedicineHumansKidney transplantationTransplantationLeukopeniabusiness.industryImmunosuppressionMiddle AgedMycophenolic Acidmedicine.diseaseKidney TransplantationTacrolimusTransplantationsurgical procedures operativeDrug Therapy CombinationFemaleSteroidsPancreas Transplantationmedicine.symptombusinessmedicine.drugTransplant International
researchProduct

Complications in Immunosuppressive Therapy of Liver Transplant Recipients

2011

BACKGROUND: In liver transplantation (LT), modern immunosuppressive protocol is focused on early corticosteroid (CS) weaning. The aim of the study was to investigate all early transplant-related complications using Clavien grading system, in order to identify a significant relation in two homogenous groups of consecutive liver transplanted patients, only different for steroid avoidance in immunosuppressive regimen. MATERIALS AND METHODS: One group was treated with a tacrolimus-based CS-free immunosuppressive protocol, the other one underwent tacrolimus plus low dose CS therapy. The preoperative continuous variables analyzed were age, gender, model for end-stage liver disease (MELD) score, a…

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatecomplicationLiver transplantationGastroenterologyTacrolimusYoung AdultLiver diseasePostoperative ComplicationsAdrenal Cortex HormonesInternal medicinemedicineHumansAgedRetrospective Studiesimmunosuppressionbusiness.industryIncidenceLiver DiseasesIncidence (epidemiology)ImmunosuppressionMiddle Agedmedicine.diseaseTacrolimusLiver TransplantationSurgerySurvival RateRegimenCorticosteroidDrug Therapy CombinationFemaleSurgeryrejectionComplicationbusinessImmunosuppressive AgentsJournal of Surgical Research
researchProduct

Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?

2012

Abstract Background Immunosuppressive therapy after orthotopic liver transplantation (OLT) requires a high degree of patient compliance to guarantee safety and avoid side effects. In 2007, prolonged-release tacrolimus was launched in Europe to improve compliance. In this prospective observational crossover single-center trial, we analyzed effects and side effects of prolonged-release tacrolimus in OLT patients. Methods LT patients at our center were included if they were older than l8 years of age, had had the procedure at least 6 months prior, and were outpatients currently on twice-daily tacrolimus. Patients were observed for 6 months before switching to once-daily tacrolimus. Patient his…

AdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentChemistry Pharmaceuticalchemical and pharmacologic phenomenaLiver transplantationGastroenterologyTacrolimuschemistry.chemical_compoundPharmacotherapyDiabetes mellitusInternal medicineGermanymedicineHumansMedical historyProspective StudiesProspective cohort studyAgedTransplantationCross-Over Studiesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseCrossover studyTacrolimusSurgeryLiver Transplantationsurgical procedures operativeTreatment OutcomechemistryDelayed-Action PreparationsSurgeryDrug Therapy CombinationFemaleGlycated hemoglobinbusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical &amp; Gynecological Survey
researchProduct